Teva Pharmaceutical Industries (NYSE:TEVA) Announces Quarterly Earnings Results

Teva Pharmaceutical Industries (NYSE:TEVA) issued its earnings results on Wednesday. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.06), FiscalAI reports. The business had revenue of $4.14 billion during the quarter, compared to analyst estimates of $4.02 billion. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.59%. Teva Pharmaceutical Industries’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.66 EPS. Teva Pharmaceutical Industries updated its FY 2026 guidance to 1.910-2.110 EPS.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

• Innovative products drove growth: AUSTEDO, UZEDY, and AJOVY delivered strong Q2 increases, prompting Teva to raise their combined 2026 revenue outlook by approximately $150 million at the midpoint. AUSTEDO revenue rose 40% globally, UZEDY 43%, and AJOVY 56% year over year.
• Teva raised its full-year 2026 revenue guidance midpoint by $75 million and reported $622 million of free cash flow, up 31% year over year. Management reaffirmed its targets of a 30% non-GAAP operating margin, net debt/EBITDA below 2x, and 80% cash conversion by 2027.
• The development pipeline is advancing, with potential submissions or launches including olanzapine LAI in late 2026, ecopipam for Tourette syndrome in 2027, and additional programs through 2030. Teva also expanded duvakitug development into hidradenitis suppurativa and fibrostenotic Crohn’s disease, while anti-IL-15 programs remain active in vitiligo and celiac disease.
• Generics revenue declined 15% year over year, primarily because of lower generic REVLIMID contributions, although management said the underlying generics business was broadly stable and biosimilars are becoming a growth platform. Teva expects biosimilar revenue to exceed its $800 million 2027 target.
• Management expects elevated AUSTEDO channel inventory to normalize over the next two quarters and warned that Q4 AUSTEDO revenue could decline year over year amid purchasing and pricing changes ahead of IRA implementation. Higher planned operating expenses, unfavorable foreign exchange, and the $724 million Emalex acquisition-related R&D charge also pressured reported profitability.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA traded down $0.61 during mid-day trading on Friday, hitting $34.80. 1,280,326 shares of the company’s stock traded hands, compared to its average volume of 7,281,354. The firm has a market capitalization of $40.01 billion, a price-to-earnings ratio of 58.09, a price-to-earnings-growth ratio of 3.67 and a beta of 0.86. The firm has a 50 day moving average of $33.22 and a two-hundred day moving average of $32.72. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries has a 12 month low of $14.99 and a 12 month high of $37.35.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Friday, July 17th. Finally, Truist Financial boosted their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Insider Transactions at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 10,679 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the transaction, the chief accounting officer directly owned 20,016 shares in the company, valued at $720,576. This represents a 34.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the completion of the sale, the executive vice president owned 172,184 shares in the company, valued at $6,131,472.24. This represents a 47.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 300,493 shares of company stock worth $10,537,510 over the last three months. 0.54% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Teva Pharmaceutical Industries by 567.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after purchasing an additional 1,134 shares in the last quarter. Global Retirement Partners LLC lifted its position in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares during the period. Advocate Investing Services LLC acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $53,000. Finally, DV Equities LLC bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $69,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: An analyst upgrade helped drive buying interest, with the stock reported up 8.2% following the rating change. Piper Sandler also forecast significant additional price appreciation. Teva Stock Price Up Following Analyst Upgrade
• Positive Sentiment: Teva raised its 2026 revenue outlook, lifting the midpoint by $75 million. Management cited broad portfolio growth and set targets of $2.45 billion–$2.6 billion for AUSTEDO and $850 million–$870 million for AJOVY. Teva Raises 2026 Revenue Outlook
• Positive Sentiment: UZEDY generated record quarterly sales, prompting Teva to increase its 2026 revenue outlook for the long-acting schizophrenia treatment. New FDA progress for a once-monthly olanzapine injection and a Tourette syndrome candidate also strengthened confidence in the pipeline. Teva Lifts UZEDY Outlook
• Positive Sentiment: Second-quarter revenue of $4.142 billion exceeded expectations, supported by innovative and branded medicines. The results reinforce management’s strategy of shifting Teva toward higher-growth branded products. Teva Lifts Sales View
• Neutral Sentiment: Options activity was unusually heavy in both directions: call purchases rose 136% on July 29, while put purchases rose 168% on July 30. The activity signals elevated investor interest but does not establish a clear consensus on the next move. Unusual Teva Options Trading
• Negative Sentiment: Teva’s earnings per share missed estimates, while the company reported a $576 million net loss versus $282 million of net income a year earlier. Emalex acquisition costs, impairment charges and other expenses weighed on profitability, creating a significant risk even as revenue guidance improved. Teva Q2 Earnings and Revenue Outlook

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.